Daniel J. Moorhead Sells 10,000 Shares of Zynex, Inc. (NASDAQ:ZYXI) Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $7.68, for a total value of $76,800.00. Following the completion of the transaction, the chief financial officer now owns 19,738 shares in the company, valued at approximately $151,587.84. This represents a 33.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Zynex Stock Up 4.3 %

ZYXI stock opened at $8.06 on Wednesday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The company has a market capitalization of $256.68 million, a price-to-earnings ratio of 53.73 and a beta of 0.53. Zynex, Inc. has a fifty-two week low of $7.15 and a fifty-two week high of $13.77. The stock has a fifty day moving average of $8.10 and a 200-day moving average of $8.18.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. R Squared Ltd bought a new stake in shares of Zynex during the 4th quarter valued at about $26,000. Gladius Capital Management LP raised its holdings in shares of Zynex by 53.4% during the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock valued at $41,000 after buying an additional 1,742 shares in the last quarter. Investment Partners Asset Management Inc. purchased a new position in Zynex in the 3rd quarter worth approximately $96,000. Hsbc Holdings PLC purchased a new position in Zynex in the 2nd quarter worth approximately $113,000. Finally, Jane Street Group LLC increased its stake in Zynex by 8.9% in the 3rd quarter. Jane Street Group LLC now owns 23,530 shares of the company’s stock worth $192,000 after purchasing an additional 1,929 shares during the period. Institutional investors own 29.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ZYXI shares. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Zynex in a research note on Friday, December 6th. Royal Bank of Canada cut their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.